Class III recommendations in guidelines for cardiovascular medicine: Difference between revisions
Jump to navigation
Jump to search
YazanDaaboul (talk | contribs) |
YazanDaaboul (talk | contribs) |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{YD}}; {{AV}} | {{CMG}}; {{AE}} {{YD}}; {{AV}} | ||
==Overview== | ==Overview== | ||
Class III recommendations are defined as conditions for which there is evidence and/or general agreement that the procedure or treatment is not useful/effective and in some cases may be harmful. Class III guidelines may be further classified by level of evidence (either A, B, or C) or by whether there is evidence of either harm or no benefit. The list of Class III recommendations is populated from all guidelines published by American cardiology societies. Out of a a total of 65 guidelines, there are 584 class III recommendations (57 LOE-A, 229 LOE-B, 277 LOE-C, and 21 of unclassified LOE). | Class III recommendations are defined as conditions for which there is evidence and/or general agreement that the procedure or treatment is not useful/effective and in some cases may be harmful. Class III guidelines may be further classified by either level of evidence (either A, B, or C) or by whether there is evidence of either harm or no benefit. The list of Class III recommendations is populated from all guidelines published by American cardiology societies. Out of a a total of 65 guidelines, there are 584 class III recommendations (57 LOE-A, 229 LOE-B, 277 LOE-C, and 21 of unclassified LOE). | ||
==Class III Recommendations in Guidelines for Cardiovascular Medicine== | ==Class III Recommendations in Guidelines for Cardiovascular Medicine== | ||
*Class III recommendations are defined as conditions for which there is evidence and/or general agreement that the procedure or treatment is not useful/effective and in some cases may be harmful. | *Class III recommendations are defined as conditions for which there is evidence and/or general agreement that the procedure or treatment is not useful/effective and in some cases may be harmful. | ||
| Line 13: | Line 14: | ||
*Class III recommendations may also be classified according to the reasoning behind the development of the recommendation, which may be due to evidence of ''no benefit'' or due to evidence of ''harm''.<br><br> | *Class III recommendations may also be classified according to the reasoning behind the development of the recommendation, which may be due to evidence of ''no benefit'' or due to evidence of ''harm''.<br><br> | ||
*The following class III recommendations include the most recent guidelines in cardiovascular medicine published by American cardiology societies. | *The following class III recommendations include the most recent guidelines in cardiovascular medicine published by American cardiology societies. | ||
**To view the list of guidelines organized by year of publication, click [[Class III recommendations in guidelines for cardiovascular medicine list of guidelines #Organized by Year of Guideline Publication|here]]. | **To view the list of guidelines used to populate the list of recommendations and organized by year of publication, click [[Class III recommendations in guidelines for cardiovascular medicine list of guidelines #Organized by Year of Guideline Publication|here]]. | ||
**Alternatively, to view the list of guidelines organized by guideline name (keywords), click [[Class III recommendations in guidelines for cardiovascular medicine list of guidelines #Organized by Guideline Keywords|here]]. | **Alternatively, to view the list of guidelines used to populate the list of recommendations and organized by guideline name (keywords), click [[Class III recommendations in guidelines for cardiovascular medicine list of guidelines #Organized by Guideline Keywords|here]]. | ||
===List of Class III Recommendations=== | ===List of Class III Recommendations=== | ||
| Line 22: | Line 23: | ||
{{familytree | | | | | | | | | | B01 | | | | | | | | | | | |B01=[[List of Class III recommendations in guidelines for cardiovascular medicine|Class III Recommendations]]}} | {{familytree | | | | | | | | | | B01 | | | | | | | | | | | |B01=[[List of Class III recommendations in guidelines for cardiovascular medicine|Class III Recommendations]]}} | ||
{{familytree | | | |,|-|-|-|-|-|-|^|-|-|-|-|.| | | | | | | |}} | {{familytree | | | |,|-|-|-|-|-|-|^|-|-|-|-|.| | | | | | | |}} | ||
{{familytree | | | C01 | | | | | | | | | | C02 | | | | | | |C01=[[Class III recommendations in guidelines for cardiovascular medicine organized by guideline|Organized by Guideline]] | C02=[[Class III recommendations in guidelines for cardiovascular medicine organized by level of evidence|Organized by Level of Evidence]]}} | {{familytree | | | C01 | | | | | | | | | | C02 | | | | | | |C01=[[Class III recommendations in guidelines for cardiovascular medicine organized by guideline|Organized by Guideline]] | C02=[[Class III recommendations in guidelines for cardiovascular medicine organized by level of evidence|Organized by Level of Evidence (LOE)]]}} | ||
{{familytree | |,|-|^|-|.| | | |,|-|-|-|v|-|^|-|v|-|-|-|.| |}} | {{familytree | |,|-|^|-|.| | | |,|-|-|-|v|-|^|-|v|-|-|-|.| |}} | ||
{{familytree | D01 | | D02 | | D03 | | D04 | | D05 | | D06 |D01=[[Class III recommendations in guidelines for cardiovascular medicine organized by guideline keywords|Guideline Name/Keywords]] | D02=[[Class III recommendations in guidelines for cardiovascular medicine organized by year of guideline publication|Year of Publication]] | D03=[[Class III A recommendations in guidelines for cardiovascular medicine|LOE A]] | D04=[[Class III B recommendations in guidelines for cardiovascular medicine|LOE B]]| D05=[[Class III C recommendations in guidelines for cardiovascular medicine|LOE C]]| D06=[[Unclassified Class III recommendations in guidelines for cardiovascular medicine|Unclassified LOE]]}} | {{familytree | D01 | | D02 | | D03 | | D04 | | D05 | | D06 |D01=[[Class III recommendations in guidelines for cardiovascular medicine organized by guideline keywords|Guideline Name/Keywords]] | D02=[[Class III recommendations in guidelines for cardiovascular medicine organized by year of guideline publication|Year of Publication]] | D03=[[Class III A recommendations in guidelines for cardiovascular medicine|LOE A]] | D04=[[Class III B recommendations in guidelines for cardiovascular medicine|LOE B]]| D05=[[Class III C recommendations in guidelines for cardiovascular medicine|LOE C]]| D06=[[Unclassified Class III recommendations in guidelines for cardiovascular medicine|Unclassified LOE]]}} | ||
{{familytree/end}} | {{familytree/end}} | ||
<br> | |||
<br> | |||
<br> | |||
Latest revision as of 06:23, 6 May 2015
| Class III Recommendations in Guidelines for Cardiovascular Medicine |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Aparna Vuppala, M.B.B.S. [2]
Overview
Class III recommendations are defined as conditions for which there is evidence and/or general agreement that the procedure or treatment is not useful/effective and in some cases may be harmful. Class III guidelines may be further classified by either level of evidence (either A, B, or C) or by whether there is evidence of either harm or no benefit. The list of Class III recommendations is populated from all guidelines published by American cardiology societies. Out of a a total of 65 guidelines, there are 584 class III recommendations (57 LOE-A, 229 LOE-B, 277 LOE-C, and 21 of unclassified LOE).
Class III Recommendations in Guidelines for Cardiovascular Medicine
- Class III recommendations are defined as conditions for which there is evidence and/or general agreement that the procedure or treatment is not useful/effective and in some cases may be harmful.
- Class III recommendations may be further classified according to the level of evidence (LOE):
- LOE A: Defined as evidence obtained from either multiple populations, multiple randomized clinical trials, or meta-analyses of randomized clinical trials.
- LOE B: Defined as evidence obtained from either a limited number of populations, a single randomized clinical trial, or meta-analyses of non-randomized studies.
- LOE C: Defined as evidence obtained from either a very limited number of populations, consensus opinion of experts, case studies, or standard of care.
- LOE A: Defined as evidence obtained from either multiple populations, multiple randomized clinical trials, or meta-analyses of randomized clinical trials.
- Class III recommendations may also be classified according to the reasoning behind the development of the recommendation, which may be due to evidence of no benefit or due to evidence of harm.
- The following class III recommendations include the most recent guidelines in cardiovascular medicine published by American cardiology societies.
List of Class III Recommendations
| List of Guidelines | |||||||||||||||||||||||||||||||||||||||||||||||
| Class III Recommendations | |||||||||||||||||||||||||||||||||||||||||||||||
| Organized by Guideline | Organized by Level of Evidence (LOE) | ||||||||||||||||||||||||||||||||||||||||||||||
| Guideline Name/Keywords | Year of Publication | LOE A | LOE B | LOE C | Unclassified LOE | ||||||||||||||||||||||||||||||||||||||||||